Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease
Open Access
- 1 March 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (3) , 311-316
- https://doi.org/10.1023/a:1008386501738
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatmentCancer Treatment Reviews, 1996
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretionJournal of Bone and Mineral Research, 1995
- BM-21.0955, Monosodium Salt, MonohydrateDrugs of the Future, 1994
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992
- A double-blind, crossover trial of intravenous clodronate in metastatic bone painJournal of Pain and Symptom Management, 1992
- BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 1991